Arista’s operating thesis still works; the stock’s setup does not. ANET closed at $187.81 on 14 September 2026, 21.9% above the $154.03 price at which the May underwrite said BUY, so today’s decision is to hold the business and…
ArchiveThe price has barely moved, and neither has the proof. StoneX closed at $69.46 on September 4, 2026, versus $69.66 on August 26, 2026; the promoted $1.6 quadrillion annual B2B-payments flow still describes transaction value, not…
Prices moved; the underwriting did not. Across five names, this was a week in which the tape tried to outrun the evidence: the strongest move was NVIDIA, yet the reported transaction behind the review still lacked primary…
Nu's payments-to-banking thesis remains plausible, but the evidence still does not establish that credit economics justify paying more for it. With the shares now above the level in the original review and no new qualifying…
PagBank has rallied, but the evidence still does not support upgrading a broad payments narrative into a buy. The decision today is to HOLD: wait for issuer-reported proof that banking income is improving economics without…
The reported Hugging Face deal still has no primary-source foundation in the research record. At NVIDIA’s $217.44 adjusted close on 1 September 2026, the disciplined response is HOLD: wait for a filing and deal economics, not…
The reported ~$8bn sale of Shell chemical assets is still not an investable thesis. With SHEL at $92.3748 at 7:02 a.m. ET on 1 September 2026, the right call is to wait for signed terms and a capital-allocation plan rather than…
Apple Pay may own the customer screen, but Apple still does not disclose enough payments economics to value that position separately. With AAPL closing at $319.70 on 28 August 2026, up from the memo’s $309.67 reference price on…
A busy tape did not produce a busy book. The common thread was the gap between a corporate headline and investable evidence: an alleged $12.9bn AI acquisition, a block sale, dividends, board changes and NAV prints arrived, but…
Klarna’s collapse from its 52-week high looks tempting, but the evidence is still too thin to underwrite the credit cycle. The stock is cheap only relative to where it traded—not yet relative to verified earnings power.
The drone-delivery story does not change the Uber call today. End-2026 launch timing and a 2029 scale target may be strategically interesting, but neither establishes approvals, cost savings or unit economics; at the latest…
The market can price a strategy before management explains it, but investors should not pay for an unverified one. Deutsche Bank's reported commodities rebuild still lacks primary confirmation or evidence of financial…
Walmart’s U.S. operating-chief change remains real but financially unproven; the stock price is doing far more work than that personnel story. At the 24 August 2026 close, the sensible decision is to wait for margin and…
JPMorgan’s operating quarter remains excellent; the valuation is the constraint. At $351.58 at the 21 August 2026 close, the shares trade at roughly 3.1× Q2’26 tangible book value, so the right call is to wait for either a better…
Coinbase’s diversification thesis still works, but the stock has moved faster than the evidence. With no newer operating filing than Q2 2026 and COIN up 25.4% from the research cutoff to the latest completed-session close, the…
The melanoma signal is real; the certainty being sold around it is not. Moderna closed at $145.13 on 21 August 2026 after touching $159.47, but the evidence under review is sustained Phase 2b efficacy, not a completed Phase 3…
The week split cleanly between evidence that can be underwritten and headlines that cannot. Lockheed Martin remains the book’s sole BUY because demand is quantified and filed operating capacity is visible; a fresh batch of…
XOM’s operating case is stronger than it was in July; the price case is not. Record Permian output and Q2 cash generation validate the company-specific thesis, but at $166.15 the stock still asks buyers to underwrite a…
The Patriot thesis has barely moved while the share price has: Lockheed Martin closed at $589.15 on August 19, 2026, only 1.1% above the $582.74 August 1 close used in my original BUY. Nothing in the evidence has weakened the…
AMD's AI-infrastructure thesis is still alive, but the stock has not offered the price needed to underwrite its execution risk. Since my 3 August issue, AMD has moved from $476.15 to a $484.39 close on 18 August 2026; the…
Merck’s post-Keytruda bridge is becoming more credible: Q2’26 sales grew, KEYTRUDA held its trajectory, and WINREVAIR accelerated. The stock has also moved beyond the price that offered a margin of safety, so the call changes…
Alphabet’s AI buildout has crossed from an earnings debate into a cash-flow test: Q2’26 operating cash flow did not cover capital expenditure, even though the trailing twelve months remained strongly cash-generative. The shares…
The Intel story being circulated is a financing story without the financing document. Until the claimed upsized raise can be tied to an SEC filing and its dilution can be calculated, the only defensible decision is to stay out.
Phase 1C is improving TransJamaican Highway's earnings, but the evidence does not support paying any price for that growth. The right call is TRIM at the newsletter's J$13 reference: keep exposure to the cash-generating road, but…
The week split cleanly between evidence and headlines. Coinbase’s diversification produced the only actionable valuation-and-fundamentals combination; Lilly and ASML kept executing but still demand too much perfection, while a…
The Grant Thornton takeout still offers CBIZ holders $55.00 in cash, but CBZ closed at $54.60 on 13 August 2026. That leaves just 0.73% gross upside before time, taxes or deal risk: enough to hold, not enough to initiate.
Lilly’s obesity franchise is executing at a level few large-cap drug companies ever reach. The decision is nevertheless HOLD: at $1,220.28 as of the 12 August 2026 close, investors are still paying for years of near-flawless…
ASML’s operating outlook improved much faster than the share-price margin of safety. The company’s 2026 sales and gross-margin upgrades strengthen the franchise case, but at the last sourced price the stock already requires a…
The market still prices Coinbase like a crypto trading venue. The more interesting evidence is that it is becoming a broader financial rail—and the stock now offers a defined, if high-risk, entry.
On Friday AMD gapped up to $510.27, traded as high as $515.62, and then crashed intraday to close at $476.15 — a 7.5% reversal in one session from the open. That is not how a stock behaves when investors are comfortable with the…
Every memo in your inbox as it publishes. Free.